There's lots happening in Adoptive T-cell transfer technology cancer research - CAR-T being just one aspect

There's lots happening in Adoptive T-cell transfer technology cancer research - CAR-T being just one aspect

When Dr Carl June of the University of Pennsylvania, used chimeric antigen receptor (CAR) technology to provide an amazing cure in a CAR-T trial in 2011 for three CLL patients that had pretty well run out of options

uphs.upenn.edu/news/News_Re...

there were valid concerns that the extremely high costs of this personalised form of immunotherapy would make it very difficult to translate into a readily available treatment option.

Nevertheless, efforts have continued to expand the ways in which this technology can be used and to find approaches to reduce the per patient cost. Here's a summary on these efforts from the 1-day Cancer Immunotherapy: A Long Awaited Reality Conference, held at the New York Academy of Medicine on March 27 on the different Engineered T-Cell Immunotherapy Approaches in Cancer:

cancernetwork.com/news/engi...

Neil

Last edited by

1 Reply

oldestnewest
  • Yes costs make a lot of difference, especially here in the UK, but this issue is understood and is being approached. All the trials, some will not work but some will, are what gives hope to us cll'ers. Best wishes

You may also like...